6CM
PHAT icon

683 Capital Management’s Phathom Pharmaceuticals PHAT Stock Holding History

683 Capital Management’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.1M Hold
1,850,000
– – 0.99% 26
2026
Q1 		$20.6M Buy
1,850,000
+65,000
+4% +$821K 1.07% 21
2025
Q4 		$29.6M Sell
1,785,000
-35,380
-2% -$505K 1.29% 17
2025
Q3 		$21.4M Sell
1,820,380
-284,620
-14% -$2.94M 1.12% 25
2025
Q2 		$20.2M Buy
2,105,000
+660,000
+46% +$3.65M 1.33% 18
2025
Q1 		$9.06M Buy
1,445,000
+420,000
+41% +$2.55M 0.62% 47
2024
Q4 		$8.32M Buy
1,025,000
+15,000
+1% +$186K 0.52% 50
2024
Q3 		$18.3M Sell
1,010,000
-390,000
-28% -$5.45M 1.39% 22
2024
Q2 		$14.4M Sell
1,400,000
-250,000
-15% -$2.57M 1.09% 28
2024
Q1 		$17.5M Buy
1,650,000
+370,000
+29% +$3.14M 1.28% 26
2023
Q4 		$11.7M Buy
1,280,000
+180,000
+16% +$1.55M 0.96% 40
2023
Q3 		$11.4M Sell
1,100,000
-187,500
-15% -$2.57M 0.89% 37
2023
Q2 		$18.4M Sell
1,287,500
-38,000
-3% -$438K 1.32% 22
2023
Q1 		$9.46M Sell
1,325,500
-24,500
-2% -$215K 0.7% 41
2022
Q4 		$15.1M Sell
1,350,000
-313,943
-19% -$3.24M 1.28% 21
2022
Q3 		$18.4M Buy
1,663,943
+223,943
+16% +$2.13M 1.42% 23
2022
Q2 		$12.2M Buy
1,440,000
+1,085,000
+306% +$11.2M 0.86% 36
2022
Q1 		$4.83M Buy
355,000
+64,405
+22% +$1.04M 0.26% 82
2021
Q4 		$5.72M Buy
+290,595
New +$6.84M 0.21% 85

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

683 Capital Management's PHAT Position: Q2 2026 in Review

683 Capital Management held its Phathom Pharmaceuticals (PHAT) position steady in Q2 2026 at 1,850,000 shares worth $20.1M. The position accounts for 0.99% of the portfolio, ranked #26.

683 Capital Management first reported a position in PHAT in Q4 2021 and has held it in 19 quarters since. The position peaked at $29.6M in Q4 2025. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • 683 Capital Management held 1,850,000 shares of Phathom Pharmaceuticals worth $20.1M as of Q2 2026.
  • 683 Capital Management left its Phathom Pharmaceuticals share count unchanged in Q2 2026.
  • Phathom Pharmaceuticals made up 0.99% of 683 Capital Management's portfolio in Q2 2026, its #26 holding.
  • 683 Capital Management first reported a position in Phathom Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
  • 683 Capital Management's Phathom Pharmaceuticals position peaked at $29.6M in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.